Mirum Pharmaceuticals Inc (MIRM)
25.11
-0.36
(-1.41%)
USD |
NASDAQ |
May 24, 10:10
Mirum Pharmaceuticals Cash from Operations (Quarterly): 15.21M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 15.21M |
| December 31, 2023 | -16.62M |
| September 30, 2023 | -18.22M |
| June 30, 2023 | -17.33M |
| March 31, 2023 | -18.77M |
| December 31, 2022 | -34.27M |
| September 30, 2022 | -26.02M |
| June 30, 2022 | -20.17M |
| March 31, 2022 | -39.67M |
| December 31, 2021 | -33.15M |
| September 30, 2021 | -34.20M |
| Date | Value |
|---|---|
| June 30, 2021 | -40.20M |
| March 31, 2021 | -25.21M |
| December 31, 2020 | -36.28M |
| September 30, 2020 | -17.45M |
| June 30, 2020 | -16.99M |
| March 31, 2020 | -18.35M |
| December 31, 2019 | -13.70M |
| September 30, 2019 | -15.22M |
| June 30, 2019 | -8.017M |
| March 31, 2019 | -2.426M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-40.20M
Minimum
Jun 2021
15.21M
Maximum
Mar 2024
-21.73M
Average
-18.56M
Median
Cash from Operations (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | 7.569M |
| Sarepta Therapeutics Inc | -242.08M |
| Puma Biotechnology Inc | 11.25M |
| Reneo Pharmaceuticals Inc | -21.01M |
| Tharimmune Inc | -2.825M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.013M |
| Cash from Financing (Quarterly) | 1.205M |
| Free Cash Flow | -42.04M |
| Free Cash Flow Per Share (Quarterly) | 0.3239 |
| Free Cash Flow to Equity (Quarterly) | 14.78M |
| Free Cash Flow to Firm (Quarterly) | 15.20M |
| Free Cash Flow Yield | -3.88% |